CagriSema at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
CagriSema is a fixed-dose combination investigational therapy developed by Novo Nordisk, pairing cagrilintide (a long-acting amylin analog) with semaglutide 2.4mg. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that reduces food intake, slows gastric emptying, and suppresses glucagon - mechanisms that are complementary to but distinct from GLP-1 receptor agonism.
The rationale for CagriSema is mechanistic synergy: GLP-1 receptor agonism and amylin receptor agonism act on different brainstem and hypothalamic circuits to reduce appetite. Clinical data from the REDEFINE 1 Phase 3 trial (2024) showed mean body weight loss of 22.7% at 68 weeks - approaching retatrutide's Phase 2 results and substantially exceeding semaglutide alone. Gastrointestinal tolerability was broadly similar to semaglutide monotherapy.
CagriSema remains investigational and has not yet received FDA or EMA approval. Novo Nordisk is pursuing regulatory submission based on the Phase 3 program. Its arrival would represent a meaningful addition to the GLP-1 class, offering semaglutide-level tolerability with tirzepatide-or-better weight loss efficacy.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.